A cikin 'yan shekarun nan, tare da haɓakar haɓakar ingantattun magunguna da fasahar bincike ta in vitro, buƙatar kasuwa don sake samar da hematology, a matsayin ainihin abubuwan da ake buƙata don gwajin asibiti, ya ci gaba da haɓaka. Daban-daban na reagents na hematology suna da bambance-bambance masu mahimmanci a cikin yanayin aikace-aikacen, ka'idodin fasaha da alamun aiki. Fahimtar waɗannan bambance-bambance yana da mahimmanci ga cibiyoyin kiwon lafiya, masu rarrabawa da masu amfani da ƙarshe.
Daga hangen nesa na wuraren aikace-aikace, reagents reagents yawanci sun kasu kashi uku: gwaje-gwajen jini na yau da kullun, nazarin aikin coagulation, da gwajin immunohematology. Reagents na yau da kullun na jini suna gano ƙwayoyin jajayen jini, fararen jini da sigogin platelet. Fasahar ta balaga kuma matakin daidaitawa yana da girma, tare da ƙimar shigar kasuwa fiye da 80%. Ayyukan coagulation reagents suna mai da hankali kan alamomi kamar lokacin coagulation da fibrinogen, kuma suna da matuƙar buƙatu don kwanciyar hankali da hankali. Ana amfani da su sau da yawa don tantancewa kafin a yi aiki da kuma lura da maganin cututtukan jini. Immunohematology reagents kamar katin buga jini da antibody screen reagents sun dogara da ka'idar antigen{6}}antibody dauki kuma ba za a iya maye gurbinsu ba a fagen aminci na ƙarin jini.
A fasaha, ana iya raba reagents na jini zuwa kashi uku: Hanyar sinadarai, immunoturbidimetry da kuma hanyar nazarin kwayoyin halitta. Reagents na sinadarai suna da ƙarancin farashi kuma sun dace da gwaji na asali a cibiyoyin kiwon lafiya na farko, amma suna da sauƙi ga tsangwama samfurin. Immunoturbidimetry yana amfani da antigen - antibody daure don samar da sauye-sauyen turbidity don ƙididdigar ƙididdiga, tare da ingantacciyar fahimta, zama babban zaɓi a tsakiyar -zuwa-mafi-karshen kasuwa. Reagents na kwayoyin halitta kamar su PCR{7} samfurori masu alaƙa suna iya gano maye gurbi ko ƙwayoyin ƙwayoyin cuta. Ko da yake suna da tsada, ba makawa ba ne a cikin buga cutar sankarar bargo da kuma tantance cututtukan ƙwayoyin cuta.
Dangane da ma'auni masu inganci, takaddun shaida na duniya kamar CE da FDA sune maɓalli masu mahimmanci don samun kasuwa. Bukatun tsari sun bambanta sosai a ƙasashe ko yankuna daban-daban. Misali, EU tana da tsauraran iko akan bambance-bambancen batch na reagents, yayin da Amurka ta fi mai da hankali kan amincin bayanan ingantattun asibiti. Bugu da kari, yanayin ajiya (kamar 2-8 digiri ko -20 digiri) da rayuwar shiryayye na reagents suma suna shafar yanke shawara kai tsaye.
A nan gaba, tare da haɗin gwiwar fasahar microfluidics da algorithms na hankali na wucin gadi, reagents na hematology za su haɓaka a cikin hanyar gwaji mai sauri da bincike ta atomatik. Masu rarrabawa suna buƙatar kula da hankali sosai ga yanayin haɓakar fasaha da kuma taimaka wa abokan ciniki su dace da mafi dacewa mafita na reagent don samun fa'ida a gasar.